Articles by Jim Miller - BioPharm International

ADVERTISEMENT

ADVERTISEMENT

Articles by Jim Miller

Drug Approval Trends Don't Extend to CMOs

Approvals of new drugs are on an upward swing, but only a few CMOs are benefiting.
Jun 1, 2013

Approvals of new drugs are on an upward swing, but only a few CMOs are benefiting.

Strategic Partnering for Manufacturing

An innovative approach to capacity management.
Apr 1, 2013

An innovative approach to capacity management.

End of the Dedicated CMO?

Is the contract-only CMO an endangered species?
Feb 1, 2013

Is the contract-only CMO an endangered species?

Sizing the Market for Contract Manufacturing

Measuring the size of the market for contract manufacturing services requires a careful hand.
Oct 1, 2012

Measuring the size of the market for contract manufacturing services requires a careful hand.

The Macro View

The weak global economy adds to the challenges of bio/pharma companies and their suppliers.
Sep 1, 2012

The weak global economy adds to the challenges of bio/pharma companies and their suppliers.

Channeling Steve Jobs

Service providers must focus on delivering a superior customer experience.
May 1, 2012

Service providers must focus on delivering a superior customer experience.

CMOs Face a Kodak Moment

The evolving bio/pharmaceutical business model poses risk for CMOs.
Mar 1, 2012

The evolving bio/pharmaceutical business model poses risk for CMOs.

Contract Services in 2012

Some recent private-equity buyouts of CROs show both the upside and downside for investors.
Jan 1, 2012

Some recent private-equity buyouts of CROs show both the upside and downside for investors.

Troublesome Signs for Bio/Pharmaceutical R&D

A dearth of late-stage candidates could hurt the pharmaceutical services market in the future.
Dec 1, 2011

A dearth of late-stage candidates could hurt the pharmaceutical services market in the future.

ADVERTISEMENT

ADVERTISEMENT

Click here